Skip to main content

TUKYSA

Generic: tucatinib

Verified·Oct 26, 2026
NDC
51144-001
RxCUI
2361290
Route
ORAL
ICD-10 indication
C50.919

Affordability Check

How much will you actually pay for TUKYSA?

In 30 seconds, see every legitimate way to afford TUKYSA — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About TUKYSA

What is this medication? TUKYSA is a prescription medicine used to treat adults with HER2-positive breast cancer that is advanced or has spread to other parts of the body, including the brain. It is typically prescribed for patients whose cancer cannot be removed by surgery and who have already received one or more other anti-HER2-based treatments. This medication is taken in combination with two other drugs, trastuzumab and capecitabine, to help manage the disease.

This drug is also used to treat adults with a specific type of HER2-positive colorectal cancer that has spread or is unresectable. It is intended for patients with RAS wild-type tumors that have progressed after treatment with certain types of chemotherapy. When used for colorectal cancer, TUKYSA is administered in combination with trastuzumab to block the signals that encourage cancer cells to grow and divide.

Copay & patient assistance

  • Patient Copay Amount: Not Publicly Available
  • Maximum Annual Benefit Limit: Not Publicly Available
  • Core Eligibility Restrictions: Residents of the United States only; services only available for certain Pfizer Oncology medications
  • RxBIN, PCN, and Group numbers: Not Publicly Available

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How TUKYSA appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-08-31).

Covered by plans

51%

2,779 of 5,499 plans

Most common tier

Tier 5

On 79% of covering formularies

Prior authorization required

99%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)59
18%
Tier 2 (generic)2
1%
Tier 4 (non-preferred brand)7
2%
Tier 5 (specialty)259
79%
Tier 61
0%

Step therapy: 0% of formularies

Quantity limits: 88% of formularies

Coverage breadth: 328 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

—

Medicare Part D

———

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.